We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

130 hedge funds and large institutions have $732M invested in Revance Therapeutics, Inc. in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more call options, than puts

Call options by funds: $1.66M | Put options by funds: $869K

37% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 38

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

10% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 21

3% less funds holding

Funds holding: 134 → 130 (-4)

12% less capital invested

Capital invested by funds: $828M → $732M (-$96.2M)

Holders
130
Holders Change
-4
Holders Change %
-2.99%
% of All Funds
2.86%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
19
Increased
52
Reduced
38
Closed
21
Calls
$1.66M
Puts
$869K
Net Calls
+$791K
Net Calls Change
+$1.23M

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$35.2M
2
Goldman Sachs
Goldman Sachs
New York
+$12.9M
3
PAI
Palo Alto Investors
California
+$10.9M
4
BlackRock
BlackRock
New York
+$6.59M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$5.4M

Top Sellers

Rank Fund Capital Flow
1
ACH
ArrowMark Colorado Holdings
Colorado
-$21.7M
2
NCM
NovaQuest Capital Management
North Carolina
-$19.8M
3
PC
Polar Capital
United Kingdom
-$15M
4
DM
Deerfield Management
New York
-$14.6M
5
BAMCO Inc
BAMCO Inc
New York
-$6.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
Principal Financial Group
26
Principal Financial Group
Iowa
$5.97M -$277K -13,409 -3%
N
27
Nuveen
North Carolina
$5.2M +$507K +24,534 +8%
Charles Schwab
28
Charles Schwab
California
$4.52M +$741K +35,815 +13%
PPA
29
Parametric Portfolio Associates
Washington
$3.99M -$1.39M -67,150 -20%
State of Wisconsin Investment Board
30
State of Wisconsin Investment Board
Wisconsin
$3.98M +$434K +21,000 +8%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$3.88M -$1.37M -66,006 -20%
OCM
32
Osterweis Capital Management
California
$3.43M +$452K +21,830 +10%
CS
33
Candriam SCA
Luxembourg
$3.41M – – –
RPAM
34
Rhenman & Partners Asset Management
Sweden
$3.26M -$621K -30,000 -12%
Ameriprise
35
Ameriprise
Minnesota
$2.9M -$446K -21,567 -10%
Deutsche Bank
36
Deutsche Bank
Germany
$2.6M +$417K +20,150 +13%
Two Sigma Investments
37
Two Sigma Investments
New York
$1.89M +$1.57M +76,065 +147%
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$1.71M +$826K +39,949 +53%
EGI
39
EAM Global Investors
California
$1.63M -$548K -26,504 -19%
CSS
40
Cubist Systematic Strategies
Connecticut
$1.6M +$1.29M +62,350 +135%
SEI Investments
41
SEI Investments
Pennsylvania
$1.57M -$104K -5,020 -5%
EIM
42
Essex Investment Management
Massachusetts
$1.48M +$2.07M +100,000 New
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$1.39M +$122K +5,900 +7%
Swiss National Bank
44
Swiss National Bank
Switzerland
$1.33M +$22.8K +1,100 +1%
TCM
45
Tekla Capital Management
Massachusetts
$1.27M – – –
EI
46
EAM Investors
California
$1.26M -$416K -20,127 -19%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$1.21M +$281K +13,577 +20%
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$1.16M +$203K +9,832 +14%
KOCAA
49
Knights of Columbus Asset Advisors
Connecticut
$974K -$852K -41,184 -39%
CS
50
Credit Suisse
Switzerland
$881K +$507K +24,528 +70%
1
2
3 4 5

RVNC Hedge Fund Activity: Q1 2020 in Review

130 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2020, worth a combined $732M — down 12% from $828M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of RVNC and 19 opened new positions — a net loss of 2 holders — while 38 trimmed existing stakes and 52 added.

The largest buyer was Jennison Associates, opening a new position worth an estimated $35.2M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $21.7M.

  • 130 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2020, down from 134 in Q4 2019.
  • Funds reported $732M of Revance Therapeutics, Inc. stock for Q1 2020, down 12% quarter-over-quarter.
  • 19 funds opened new Revance Therapeutics, Inc. positions in Q1 2020 and 21 closed out, a net change of -2 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q1 2020 was Jennison Associates, an estimated $35.2M added.
  • The largest Revance Therapeutics, Inc. seller in Q1 2020 was ArrowMark Colorado Holdings, an estimated $21.7M sold.

Based on aggregated 13F filings for Q1 2020.